Memgen announced that the ongoing Phase Ib study of its cancer immune therapy, ISF35, has produced crashing results, including a perfect
quiescence in the trial's first patient who had 17p deleted chronic lymphocytic leukemia (CLL). The study, which is co-sponsored by the Leukemia & Lymphoma Society, assesses the ability of ISF35 to re-sensitize refractory and/or 17p deleted CLL to chemotherapy.